Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Balaxi PharmaceuticalsNSE:BALAXI -2.27%65 Debt-to-EBITDA is 4.74 as of Mar. 2026, which is 421% above its 10-year median of 0.91. GuruFocus rates NSE:BALAXI with a GF Score™ of 65/100 and a GF Value™ of ₹68.98 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 682 Drug Manufacturers companies, Balaxi Pharmaceuticals ranks worse than 80.5% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Balaxi Pharmaceuticals's Debt-to-EBITDA or its related term are showing as below:
NSE:BALAXI'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.07 Med: 0.91 Max: 5.08
Current: 5.08
During the past 12 years, the highest Debt-to-EBITDA Ratio of Balaxi Pharmaceuticals was 5.08. The lowest was 0.07. And the median was 0.91.
NSE:BALAXI's Debt-to-EBITDA is ranked worse than 80.5% of 682
companies
in the Drug Manufacturers industry
Industry Median: 1.63
vs NSE:BALAXI: 5.08
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Balaxi Pharmaceuticals Debt-to-EBITDA Related Terms
Balaxi Pharmaceuticals Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Balaxi Pharmaceuticals's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Balaxi Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Balaxi Pharmaceuticals Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Balaxi Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Balaxi Pharmaceuticals's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Balaxi Pharmaceuticals (NSE:BALAXI) has a Debt-to-EBITDA of 4.74 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Balaxi Pharmaceuticals. This is 421% above median its historical median of 0.91. Over the past decade, Balaxi Pharmaceuticals' Debt-to-EBITDA has ranged from 0.07 to 5.08. According to the industry distribution chart, Balaxi Pharmaceuticals ranks #549 out of 682 companies in the Drug Manufacturers industry, placing it in the top 80.5%.
Is Balaxi Pharmaceuticals' Debt-to-EBITDA too high?
Balaxi Pharmaceuticals' current Debt-to-EBITDA of 4.74 is 421% above median its 10-year median of 0.91. Over the past 10 years, this metric has ranged from a low of 0.07 to a high of 5.08. The Drug Manufacturers industry median Debt-to-EBITDA is 1.63. Balaxi Pharmaceuticals' value of 4.74 is 190.8% above this industry median. Based on the distribution chart, Balaxi Pharmaceuticals ranks #549 out of 682 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Balaxi Pharmaceuticals has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Balaxi Pharmaceuticals' Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Balaxi Pharmaceuticals ranks #549 out of 682 companies for Debt-to-EBITDA. This places Balaxi Pharmaceuticals in the lower half of its industry. The industry median Debt-to-EBITDA is 1.63. Balaxi Pharmaceuticals' value of 4.74 is 190.8% above this benchmark. Historically, Balaxi Pharmaceuticals' own Debt-to-EBITDA has ranged from 0.07 to 5.08 over the past decade. While the company's 10-year median is 0.91 vs. the industry median of 1.63, Balaxi Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.63, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Balaxi Pharmaceuticals's current Debt-to-EBITDA of 4.74 is 190.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Balaxi Pharmaceuticals. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Balaxi Pharmaceuticals's current Debt-to-EBITDA is 4.74, which is 421% above median its own 10-year median of 0.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Balaxi Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Balaxi Pharmaceuticals (NSE:BALAXI) is currently considered Possible Value Trap. The stock's GF Value™ is ₹68.98, compared to a current price of ₹24.05 — trading 65.1% below its estimated fair value. The current Debt-to-EBITDA is 4.74, which is 421% above median its 10-year median of 0.91 and 190.8% above the Drug Manufacturers industry median of 1.63. Balaxi Pharmaceuticals' overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Balaxi Pharmaceuticals (NSE:BALAXI), the current Debt-to-EBITDA is 4.74 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Balaxi Pharmaceuticals (NSE:BALAXI) Overvalued in 2026?
Based on GuruFocus' analysis, Balaxi Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹24.05 is trading 65.1% below its estimated GF Value™ of ₹68.98.
GuruFocus considers Balaxi Pharmaceuticals to be Possible Value Trap.
Key valuation signals for NSE:BALAXI:
Debt-to-EBITDA: 4.74 (421% above median its 10-year median of 0.91)
GF Value™: ₹68.98 vs. price of ₹24.05 (65.1% below fair value)
Industry Position: 190.8% above the Drug Manufacturers median (#549 of 682)
No single metric tells the full story. See the NSE:BALAXI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Balaxi Pharmaceuticals Ltd is an Indian branded IPR-based pharmaceutical company focusing on frontier markets, with a vast and growing portfolio of prescription and OTC drugs, across multiple therapeutic segments. The company operates in single segment Specialized Wholesale. Geographically it earns key revenue from Guatemala.
65GF Score
Get the complete analysis for NSE:BALAXI
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BALAXI has been successfully added to your 
